Chlorohydroxyphenylglycine

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Citation bot 4 (talk | contribs) at 10:40, 1 February 2014 ([Cat515-dev]Add: displayauthors, year, postscript, display-authors, last10, first10, last11, first11, last12, first12, last13, first13, last14, first14, last15, first15, last16, first16, last17, first17, last18, first18, last19, first19, last20, first2...). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Chlorohydroxyphenylglycine
Names
IUPAC name
Amino(2-chloro-5-hydroxyphenyl)acetic acid
Identifiers
3D model (JSmol)
Abbreviations CHPG
ChemSpider
ECHA InfoCard 100.162.133 Edit this at Wikidata
  • InChI=1S/C8H8ClNO3/c9-6-2-1-4(11)3-5(6)7(10)8(12)13/h1-3,7,11H,10H2,(H,12,13)
    Key: UNIDAFCQFPGYJJ-UHFFFAOYSA-N
  • InChI=1/C8H8ClNO3/c9-6-2-1-4(11)3-5(6)7(10)8(12)13/h1-3,7,11H,10H2,(H,12,13)
    Key: UNIDAFCQFPGYJJ-UHFFFAOYAM
  • Clc1ccc(O)cc1C(N)C(=O)O
Properties
C8H6ClNO3
Molar mass 199.59 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

2-Chloro-5-hydroxyphenylglycine or CHPG is an agonist of the metabotropic glutamate receptors, specific for mGluR5.[1]

It is capable of directly potentiating the depolarization of hippocampal CA1 neurons induced through NMDA administration.[2]

References

  1. ^ Kammermeier, Paul J (2012). "The orthosteric agonist 2-chloro-5-hydroxyphenylglycine activates mGluR5 and mGluR1 with similar efficacy and potency". BMC Pharmacology. 12: 6. doi:10.1186/1471-2210-12-6. PMC 3416681. PMID 22642439.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  2. ^ Collingridge G.; Volianskis A.; Bannister N.; France G.; Hanna L.; Mercier M.; Tidball P.; Fang G.; Irvine M.; Costa, Blaise M.; Monaghan, Daniel T.; Bortolotto, Zuner A.; Molnár, Elek; Lodge, David; Jane, David E. (2013). "The NMDA receptor as a target for cognitive enhancement". Neuropharmacology. 64: 13–26. doi:10.1016/j.neuropharm.2012.06.051. PMID 22796429.